Human Milk Oligosaccharide Composition for Athlete Gut Microbiota Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sports supplements, including probiotics and human milk oligosaccharides (HMOs), fail to effectively support intestinal health and improve sports performance and recovery in elite athletes, particularly due to disruptions in gastrointestinal microbiota and increased risk of infections from pathogens.
Innovation Solution
A composition comprising specific doses of HMOs, such as 2'-fucosyllactose, tailored for secretors and non-secretors, along with excipients like cranberry extract and antioxidants, to promote beneficial bacterial strains and enhance intestinal health, supporting immune function and athletic performance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If probiotic compositions are administered to improve sports performance, then recovery capacity is improved, but the influence on the immune system and risk of infections is limited
Solution Approach 1:
The patent combines prebiotic HMOs with probiotic compositions to create a synergistic effect. The prebiotic component selectively stimulates beneficial bacteria while the probiotic component introduces beneficial microorganisms, together providing comprehensive immune support and infection protection that neither component achieves alone.
Solution Approach 2:
The invention uses a composite formulation containing both prebiotic HMOs and probiotic microorganisms. This composite approach allows the composition to simultaneously provide substrate for beneficial bacteria growth and introduce beneficial strains, addressing both recovery capacity and immune system reliability.
2Use of energy by moving object
If fructose-rich and artificial sweetener supplements are consumed to enhance performance, then energy availability is improved, but gastrointestinal microbiota regulation is disrupted and infection risk increases
Solution Approach 1:
The patent converts the potential harm of supplement consumption by adding prebiotic HMOs that selectively nourish beneficial bacteria. These HMOs compete with pathogenic bacteria for resources, turning the supplement regimen into a beneficial intervention that protects against infections while maintaining energy availability.
Solution Approach 2:
The prebiotic HMOs act as intermediaries between the athlete's diet and the gastrointestinal microbiota. They selectively feed beneficial bacteria without directly introducing pathogens, mediating the interaction between supplement consumption and microbial balance to prevent infections.
3Productivity
If intensive training sessions are conducted to improve sports performance, then athletic capability is enhanced, but gastrointestinal microbiota is disrupted and recovery capacity is reduced
Solution Approach 1:
The patent applies preliminary action by administering prebiotic HMOs and probiotics before and during intensive training periods. This preparatory approach establishes a resilient microbiota community that can withstand the stresses of intensive training, preventing disruption before it occurs.
Solution Approach 2:
The composition provides beforehand cushioning by introducing beneficial microorganisms and their substrates prior to training stress. This creates a protective buffer in the gastrointestinal tract that cushions against the disruptive effects of intensive training on microbiota stability.
Data Source
AI summary
The present invention relates to a composition for use in supporting and/or improving intestinal health in athletes, comprising an effective dose of at least one human milk oligosaccharide (HMO) from the group of 2'-fucosyllactose (2'-FL), 3-fucosyl lactose (3-FL), lactodifucotetraose (DF-L), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP I), lacto-N-difucohexaose II (LNDFH II), lacto- N-neodifucohexaose II (LNnDFH II), para lacto-N-neohexaose (para-LNnH), lacto-N- neooctaose (LNnO), lacto-N-fucopentaose V (LNFP V), lacto-N-neofucopentaose V (LNnFP V), 3'-sialyl-3-fusoyl lactose (F-SL), LS-tetrasaccharide a (LSTa), 3'- sialyllactose (3'-SL), or combinations thereof.